Abstract
Kruppel-like factor (KLF) 6 is a tumor-suppressor gene functionally inactivated by loss of heterozygosity, somatic mutation and/or alternative splicing that generates a dominant-negative splice form, KLF6-SV1. Wild-type KLF6 (wtKLF6) expression is decreased in many human malignancies, which correlates with reduced patient survival. Additionally, loss of the KLF6 locus in the absence of somatic mutation in the remaining allele occurs in a number of human cancers, raising the possibility that haploinsufficiency of the KLF6 gene alone contributes to cellular growth dysregulation and tumorigenesis. Our earlier studies identified the cyclin-dependent kinase inhibitor p21 as a transcriptional target of the KLF6 gene in cultured cells, but not in vivo. To address this issue, we have generated two genetic mouse models to define the in vivo role of KLF6 in regulating cell proliferation and p21 expression. Transgenic overexpression of KLF6 in the liver resulted in a runted phenotype with decreased body and liver size, with evidence of decreased hepatocyte proliferation, increased p21 and reduced proliferating cell nuclear antigen expression. In contrast, mice with targeted deletion of one KLF6 allele (KLF6+/−) display increased liver mass with reduced p21 expression, compared to wild type littermates. Moreover, in primary hepatocellular carcinoma samples, there is a significant correlation between wtKLF6 and p21 mRNA expression. Combined, these data suggest that haploinsufficiency of the KLF6 gene may regulate cellular proliferation in vivo through decreased transcriptional activation of the cyclin-dependent kinase inhibitor p21.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- KLF6:
-
Kruppel-like factor 6
- wtKLF6:
-
wild-type KLF6
- qRT–PCR:
-
quantitative real-time PCR
- WT:
-
wild type
- TG:
-
transgenic
References
Alberici P, Jagmohan-Changur S, De Pater E, Van Der Valk M, Smits R, Hohenstein P et al. (2006). Smad4 haploinsufficiency in mouse models for intestinal cancer. Oncogene 25: 1841–1851.
Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS et al. (2004). Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res 64: 3885–3891.
Bieker JJ . (2001). Kruppel-like factors: three fingers in many pies. J Biol Chem 276: 34355–34358.
Bissell DM, Guzelian PS . (1980). Phenotypic stability of adult rat hepatocytes in primary monolayer culture. Ann N Y Acad Sci 349: 85–98.
Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M et al. (2002). Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between sp1 and KLF6: their potential role in the response to vascular injury. Blood 100: 4001–4010.
Boyault S, Herault A, Balabaud C, Zucman-Rossi J . (2005). Absence of KLF6 gene mutation in 71 hepatocellular carcinomas. Hepatology 41: 681–682 author reply 682–683.
Chen C, Hyytinen E R, Sun X, Helin HJ, Koivisto PA, Frierson HF et al. (2003). Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol 162: 1349–1354.
Chen HK, Liu XQ, Lin J, Chen TY, Feng QS, Zeng YX . (2002). Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas. Ai Zheng 21: 1047–1050.
Cho YG, Kim CJ, Park CH, Yang YM, Kim SY, Nam SW et al. (2005). Genetic alterations of the KLF6 gene in gastric cancer. Oncogene 24: 4588–4590.
Difeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, Buller RE et al. (2006). E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene 25: 6026–6031.
DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL et al. (2006). Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 12: 3730–3739.
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. (1993). Waf1, a potential mediator of p53 tumor suppression. Cell 75: 817–825.
Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RH, Gerald WL . (2004). Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113: 913–923.
Ito G, Uchiyama M., Kondo M, Mori S, Usami N, Maeda O et al. (2004). Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res 64: 3838–3843.
Jeng YM, Hsu HC . (2003). KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer 105: 625–629.
Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I et al. (2004). Differentially expressed genes in nonsmall cell lung cancer: Expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 149: 98–106.
Kim Y, Ratziu V, Choi SG, Lalazar A, Theiss G, Dang Q et al. (1998). Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J Biol Chem 273: 33750–33758.
Kimmelman AC, Qiao RF, Narla G, Banno A, Lau N, Bos PD et al. (2004). Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene 23: 5077–5083.
Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S et al. (2006). Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol Nov 27 [Epub ahead of print].
Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A et al. (2004). Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 40: 1047–1052.
Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N et al. (2001). Haploinsufficiency of the PTEN tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 98: 11563–11568.
Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T et al. (2004). Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40: 667–676.
Matsumoto N, Kubo A, Liu H, Akita K, Laub F, Ramirez F et al. (2006). Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. Blood 107: 1357–1365.
Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E et al. (2005). A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 65: 1213–1222.
Narla G, Friedman SL, Martignetti JA . (2003). Kruppel cripples prostate cancer: KLF6 progress and prospects. Am J Pathol 162: 1047–1052.
Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC et al. (2001). KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294: 2563–2566.
Pan XC, Chen Z, Chen F, Chen XH, Jin HY, Xu XY . (2006). Inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) by mutation or decreased expression in hepatocellular carcinomas. J Zhejiang Univ Sci B 7: 830–836.
Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S et al. (2004). Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 126: 1090–1103.
Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C et al. (2002). Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1: 203–209.
Slavin DA, Koritschoner NP, Prieto CC, Lopez-Diaz FJ, Chatton B, Bocco JL . (2004). A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-jun proto-oncoprotein function. Oncogene 23: 8196–8205.
Song J, Kim CJ, Cho YG, Kim SY, Nam SW, Lee SH et al. (2006). Genetic and epigenetic alterations of the KLF6 gene in hepatocellular carcinoma. J Gastroenterol Hepatol 21: 1286–1289.
Venkatachalam S, Tyner SD, Pickering CR, Boley S, Recio L, French JE et al. (2001). Is p53 haploinsufficient for tumor suppression? Implications for the p53+/− mouse model in carcinogenity testing. Toxicol Pathol 29 (Suppl): 147–154.
Walthall K, Cappon GD, Hurtt ME, Zoetis T . (2005). Postnatal development of the gastrointestinal system: A species comparison. Birth Defects Res B Dev Reprod Toxicol 74: 132–156.
Wang SP, Chen XP, Qiu FZ . (2004). A candidate tumor suppressor gene mutated in primary hepatocellular carcinoma: Kruppel-like factor 6. Zhonghua Wai Ke Za Zhi 42: 1258–1261.
Warke VG, Nambiar MP, Krishnan S, Tenbrock K, Geller DA, Koritschoner NP et al. (2003). Transcriptional activation of the human inducible nitric-oxide synthase promoter by Kruppel-like factor 6. J Biol Chem 278: 14812–14819.
Wu H, Wade M, Krall L, Grisham J, Xiong Y, Van Dyke T . (1996). Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration. Genes Dev 10: 245–260.
Acknowledgements
Grant support: SLF: NIH DK37340, the Bendheim Foundation and the Department of Defense, DAMD17-03-1-0100. Xiao Zhao and Goutham Narla were each supported by a Howard Hughes Medical Institute Medical Student Research Fellowship.
Author information
Authors and Affiliations
Corresponding author
Additional information
Competing interests statements
The authors disclose that they have no competing financial interests.
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Narla, G., Kremer-Tal, S., Matsumoto, N. et al. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene 26, 4428–4434 (2007). https://doi.org/10.1038/sj.onc.1210223
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210223
Keywords
This article is cited by
-
KLF6 facilitates differentiation of odontoblasts through modulating the expression of P21 in vitro
International Journal of Oral Science (2022)
-
Berberine regulates the protein expression of multiple tumorigenesis-related genes in hepatocellular carcinoma cell lines
Cancer Cell International (2017)
-
Krüppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury
Scientific Reports (2017)
-
Targeted knockdown of DJ-1 induces multiple myeloma cell death via KLF6 upregulation
Apoptosis (2016)
-
Krüppel-like factors in hepatocellular carcinoma
Tumor Biology (2015)